BNP Paribas Financial Markets’s La Jolla Pharmaceutical Company LJPC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-1
| Closed | -$3 | – | 5150 |
|
|
2022
Q2 | $3 | Hold |
1
| – | – | ﹤0.01% | 4078 |
|
|
2022
Q1 | $4 | Sell |
1
-30,733
| -100% | -$134K | ﹤0.01% | 4138 |
|
|
2021
Q4 | $143K | Buy |
30,734
+30,535
| +15,344% | +$127K | ﹤0.01% | 3492 |
|
|
2021
Q3 | $794 | Sell |
199
-3,049
| -94% | -$12.1K | ﹤0.01% | 3893 |
|
|
2021
Q2 | $13.9K | Buy |
3,248
+476
| +17% | +$2.04K | ﹤0.01% | 3638 |
|
|
2021
Q1 | $11.8K | Sell |
2,772
-1,147
| -29% | -$6.32K | ﹤0.01% | 3817 |
|
|
2020
Q4 | $15.2K | Sell |
3,919
-479
| -11% | -$2.05K | ﹤0.01% | 3885 |
|
|
2020
Q3 | $17.7K | Buy |
4,398
+3,302
| +301% | +$13.7K | ﹤0.01% | 3865 |
|
|
2020
Q2 | $4.67K | Sell |
1,096
-5,276
| -83% | -$32.1K | ﹤0.01% | 4033 |
|
|
2020
Q1 | $26.8K | Buy |
6,372
+3,378
| +113% | +$21.3K | ﹤0.01% | 3822 |
|
|
2019
Q4 | $11.8K | Sell |
2,994
-381
| -11% | -$2.25K | ﹤0.01% | 4110 |
|
|
2019
Q3 | $29.7K | Buy |
3,375
+946
| +39% | +$8.94K | ﹤0.01% | 3761 |
|
|
2019
Q2 | $22.5K | Sell |
2,429
-2,034
| -46% | -$15.3K | ﹤0.01% | 3853 |
|
|
2019
Q1 | $28.7K | Buy |
4,463
+4,456
| +63,657% | +$29K | ﹤0.01% | 3793 |
|
|
2018
Q4 | $66 | Sell |
7
-723
| -99% | -$10.9K | ﹤0.01% | 4228 |
|
|
2018
Q3 | $14.7K | Hold |
730
| – | – | ﹤0.01% | 3564 |
|
|
2018
Q2 | $21.3K | Sell |
730
-2,944
| -80% | -$90.9K | ﹤0.01% | 3474 |
|
|
2018
Q1 | $109K | Buy |
3,674
+55
| +2% | +$1.77K | ﹤0.01% | 3134 |
|
|
2017
Q4 | $116K | Buy |
3,619
+1,883
| +108% | +$61.5K | ﹤0.01% | 3224 |
|
|
2017
Q3 | $60.4K | Sell |
1,736
-116
| -6% | -$3.73K | ﹤0.01% | 3044 |
|
|
2017
Q2 | $55.1K | Buy |
1,852
+1,784
| +2,624% | +$51.1K | ﹤0.01% | 3138 |
|
|
2017
Q1 | $2.03K | Sell |
68
-711
| -91% | -$18.2K | ﹤0.01% | 3540 |
|
|
2016
Q4 | $13.7K | Sell |
779
-199
| -20% | -$3.81K | ﹤0.01% | 3324 |
|
|
2016
Q3 | $23.3K | Buy |
978
+439
| +81% | +$8.27K | ﹤0.01% | 2800 |
|
|
2016
Q2 | $8.62K | Buy |
+539
| New | +$9.67K | ﹤0.01% | 2982 |
|
|
2016
Q1 | – | Sell |
-2,956
| Closed | -$79.8K | – | 3610 |
|
|
2015
Q4 | $79.8K | Buy |
2,956
+370
| +14% | +$10.1K | ﹤0.01% | 2483 |
|
|
2015
Q3 | $71.9K | Buy |
2,586
+1,625
| +169% | +$51.2K | ﹤0.01% | 2614 |
|
|
2015
Q2 | $23.6K | Buy |
+961
| New | +$19.8K | ﹤0.01% | 2943 |
|
BNP Paribas Financial Markets's LJPC Position: Q3 2022 in Review
BNP Paribas Financial Markets sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 1 share — an estimated $3 sold.
BNP Paribas Financial Markets first reported a position in LJPC in Q2 2015 and held it in 28 quarters. The position peaked at $143K in Q4 2021. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.
- BNP Paribas Financial Markets reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
- BNP Paribas Financial Markets sold 1 La Jolla Pharmaceutical Company share in Q3 2022, an estimated $3.
- BNP Paribas Financial Markets first reported a position in La Jolla Pharmaceutical Company in Q2 2015 and held it in 28 quarters.
- BNP Paribas Financial Markets's La Jolla Pharmaceutical Company position peaked at $143K in Q4 2021.
- 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.
Based on BNP Paribas Financial Markets's 13F filing for Q3 2022, filed 15 Nov 2022.